Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels

Prostate Cancer and Prostatic Diseases

Volumn 6, Issue 1, 2003, Pages 66-72

  Gotanda, K ^a   Shinbo, A ^a   Okada, M ^a   Nakano, Y ^a   Kobayashi, H ^a   Sasaki, T ^a   Hagiwara, M ^a   Akaza, H ^b  

^a Grelan Pharmaceutical Co Ltd   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Chlormadinone acetate; Combination therapy; LH RH agonist; Prostate cancer; Testosterone

Indexed keywords

CHLORMADINONE ACETATE; FOLLITROPIN; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; FOLLITROPIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VENTRAL LOBE; RAT; SEMINAL VESICLE; TESTOSTERONE BLOOD LEVEL;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CHLORMADINONE ACETATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLICLE STIMULATING HORMONE; LEUPROLIDE; LUTEINIZING HORMONE; MALE; ORCHIECTOMY; ORGAN SIZE; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; SEMINAL VESICLES; TESTOSTERONE;

EID: 0037252187     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500617     Document Type: Article

References (18)

1. Smith JA Jr, Glode LM, Wettluafer JN, Stein BS, Glass AG, Max DT, Anbar D, Jagst CL, Murphy GP. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Urology 1985; 25: 106-114.
2. Akaza H, Isaka S, Usami M, Kanetake H, Kotake T, Koiso K, Aso Y. Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer. Int J Urol 1996; 3: 468-471.
3. Denis LJ, Keuppens F, Smith PH, Whelan P, de Moura JL, Newling D, Bono A, Sylvester R. Maximum androgen blockade: final analysis of EORTC phase III trial 30853. Eur Urol 1998; 33: 144-151.
4. Akaza H, Homma Y, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Ohashi Y, Aso Y, Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. Jpn J Clin Oncol 2000; 30: 131-136.
5. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl J Med 1989; 321: 419-424.
6. Fourcade RO, Chatelain C. Androgen deprivation for prostatic carcinoma: a rationale for choosing components. Int J Urol 1998; 5: 303-311.
7. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology 1997; 50: 330-336.
8. Debruyne FMJ, Akaza H, Fitzpatrick JM, Mahler C, Motta M, Thrasher JB, Tunn UW, Varkarakis M, van der Poel HG. Secondary hormonal therapy in prostate cancer. In: Murphy G, Khoury S, Partin A, Denis L (eds). Prostate Cancer, Health Publication Ltd: Paris, 1999, pp 395-407.
9. Shibata Y, Ito K, Suzuki K, Nakano K, Fukabori Y, Suzuki R, Kawabe Y, Honma S, Yamanaka H. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 2000; 42: 45-55.
10. Labrie F, Belanger A, Simard J, Labrie C, Dupont A. Combination therapy for prostate cancer. Cancer 1993; 71: 1059-1067.
11. Bélanger B, Bélanger A, Labrie F, Dupont A, Cusan L, Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989; 32: 695-698.
12. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164: 726-729.
13. Okada H, Heya T, Igari Y, Ogawa Y, Toguchi H, Shimamoto T. One-month release injectable microspheres of leuprolide acetate inhibit steroidogenesis and genital organ growth in rats. Int J Pharm 1989; 54: 231-239.
14. Kinoshita Y, Nishimura R, Hosaka M. A phase I study of TZP-61: single oral administration (1). Jpn Pharmacol Ther 1988; 16: 2079-2091.
15. Skinner DC, Evans NP, Delaleu. B, Goodman RL, Bouchard P, Caraty A. The negative feedback actions of progesterone on gonadotropin-releasing hormone secretion are transduced by the classical progesterone receptor. Proc Natl Acad Sci USA 1998; 95: 10978-10983.
16. Yoshida K, Takeuchi S. Pretreatment with chlormadinone acetate eliminates testosterone surge induced by a luteinizing-hormone-releasing hormone analogue and the risk of disease flare in patients with metastatic carcinoma of the prostate. Eur Urol 1995; 27: 187-191.
17. Shimada M, Uchida H, Kasahara T, Fuji K, Ogawa Y, Yoshida H, Hamajima T, Matsuda N, Ikeuchi T, Kai Y, Hiramori M, Hoshino M, Inoue K, Higaki Y. Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism. Acta Urol Jpn 1998; 44: 525-532.
18. Yamamoto A, Sumiyoshi Y, Miyake N, Yokozeki H, Kanayama H, Kagawa S. Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue. Acta Urol Jpn 1998; 44: 557-563.